GlassScriptPhysician profile
Ahmad N Kahf
NPI 1922069517
$3,924.93
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $593 · 2021: $1,158 · 2022: $777 · 2023: $752 · 2024: $44.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $788.68 | 2019-2023 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $769.18 | 2020-2023 | Austedo, Austedo Xr |
| Lilly USA, LLC | $265.23 | 2020-2023 | Jardiance, Baqsimi, Trulicity |
| Novartis Pharmaceuticals Corporation | $219.37 | 2019-2023 | |
| Amgen INC. | $217.58 | 2019-2023 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $191.86 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $133.61 | 2019-2021 | |
| Abbvie INC. | $132.65 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.53 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $95.98 | 2020-2023 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $95.39 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Ironwood Pharmaceuticals, INC | $88.06 | 2020-2021 | |
| Dexcom, INC. | $79.16 | 2021-2022 | |
| Pfizer INC. | $73.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $59.07 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.38 | 2022-2024 | Xifaxan |
| Astellas Pharma US INC | $56.20 | 2019-2021 | |
| Amarin Pharma, INC. | $53.94 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $45.97 | 2021-2022 | |
| G Medical Diagnostic Services, INC. | $42.85 | 2021-2022 | |
| Vivus LLC | $40.87 | 2021 | |
| Medtronic, INC. | $40.77 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $29.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.68 | 2019-2020 | |
| Mylan Specialty L.P. | $18.61 | 2022 | |
| Lundbeck LLC | $15.07 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $15.00 | 2020 | |
| Sanofi Pasteur INC. | $14.93 | 2019 | |
| Circassia INC. | $14.83 | 2019 | |
| Radius Health, INC. | $14.80 | 2019 | |
| Mannkind Corporation | $14.74 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.34 | 2021 | |
| Eisai INC. | $14.25 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.79 | 2023 | Rebyota |
| Eyevance Pharmaceuticals LLC | $13.76 | 2021 | |
| Hikma Pharmaceuticals USA | $13.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Kahf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.